Pliant Therapeutics (PLRX) Receivables - Other (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Receivables - Other data on file, last reported at $914000.0 in Q1 2026.

• Receivables - Other for Q1 2026 came in at $914000.0, down 45.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $914000.0 (down 45.69% YoY), and the FY2025 annual result was $823000.0, down 64.25% from the prior year.
• Receivables - Other grew to $914000.0 in Q1 2026 per PLRX's latest filing, from $823000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $4.0 million in Q3 2022 and troughed at $320000.0 in Q2 2022.
• A 5-year average of $1.8 million and a median of $1.7 million in 2025 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2025: Receivables - Other surged 639.06% in 2023, then tumbled 64.25% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.1 million in 2022, then soared by 178.01% to $3.0 million in 2023, then declined by 23.19% to $2.3 million in 2024, then plunged by 64.25% to $823000.0 in 2025, then rose by 11.06% to $914000.0 in 2026.
• Business Quant data shows PLRX's Receivables - Other at $914000.0 in Q1 2026, $823000.0 in Q4 2025, and $908000.0 in Q3 2025.